cardiovascular system
• progressive deterioration within the medial layer, with elastic fiber fragmentation and disarray of vascular smooth muscle cells begins around 2 months of age
(J:91349)
• however, no intimal hyperplasia, aortic inflammation, or aortic dissection are detected and life span is similar to wild-type mice
(J:91349)
|
• progressive fragmentation of elastic fibers within the medial wall beginning around 2 months of age
• elastic fiber calcification is occasionally seen
|
• gradual thickening of the wall due to excessive deposition of amorphous matrix and increase in the number of vascular smooth muscle cells
|
• progressive increase in leaflet length and thickness during postnatal development
• leaflet length and thickness are intermediate between homozygous mutant and wild-type mice
• cells display increased proliferation and reduced apoptosis
• in utero treatment with TGFB neutralizing antibodies at E14.5 and E17.5 rescues mitral valve morphology
|
• mitral valve prolapse and regurgitation at 9 months of age
|
• left atrium enlargement associated with mitral valve prolapse
|
• left ventricle enlargement associated with mitral valve prolapse
|
• mitral valve prolapse and regurgitation at 9 months of age
|
respiratory system
• distal airspace widening without inflammation or tissue damage
|
skeleton
• gradual postnatal development of skeletal abnormalities similar to those in other hypomorphic mouse models of Marfan Syndrome
|
• postnatal overgrowth
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
Marfan syndrome | DOID:14323 |
OMIM:154700 |
J:91349 , J:94428 |